Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can catching sleep apnea early save brain development in down syndrome?

NCT ID NCT03210675

NEW Diagnosis Sponsor: Institut Jerome Lejeune Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 21, 2026 · Last updated Sep 21, 2026

Summary

Researchers test whether checking infants with Down syndrome for obstructive sleep apnea every six months, starting at six months old, helps their brain development by age three. The trial compares a group that gets regular sleep studies to a group that receives standard care. About 80 infants in the Paris area take part, and the main measure is cognitive and motor scores at age three.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
polysomnography, a sleep study that monitors breathing and brain activity during sleep
What this could lead to
If early screening helps, doctors could routinely check infants with Down syndrome for sleep apnea to protect their brain development.
What could go wrong
The study is small and only in one city, so results may not apply everywhere. Screening itself does not treat apnea, and families must commit to repeated sleep studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

80 people

The number who actually took part.

Started

Jul 2017

Finished

Feb 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 months to 3 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria : Down Syndrome Age 6 months or less for the Study Group Age 30 to 36 months for the Standard Care Group Living in Paris or Paris area (75, 77, 78, 92, 93, 94, 95) Parents or legal representative agreeing with the study requirements and able to understand, date and sign the informed consent form before study enrollment French language is native mother tongue Exclusion criteria : Gestationnel age \< 36 completed amenorrhoea weeks Patient who have or had acute CNS suffering signs Patients with Down Syndrome already had continuous positive airway pressure treatment for OSA Patients participating in another clinical study or for whom a participation to another biomedical research is expected before the end or their follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Down syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Down syndrome obstructive sleep apnea syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Down syndrome Obstructive sleep apnea of newborn

Contacts and locations

Locations

  • Institut Jérome Lejeune

    Paris, Sélectionnez l'État/Province, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.